Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | An update on the COBRA trial: PET-response adapted treatment with brentuximab vedotin for HL

Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the positive results of the COBRA trial (NCT03517137), a Phase II study investigating PET-response adapted treatment with brentuximab vedotin-containing regimens for advanced Hodgkin lymphoma (HL). The trial showed prolonged progression-free survival (PFS) compared to the ECHELON-1 trial (NCT01712490). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.